We are open to partnering, contact our team at
With a core focus on transforming the cancer immunotherapy field.
The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatment safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets.
We are actively seeking partners for our pipeline of ground-breaking programmes and are open to partnering discussions.
Collaborating with Poolbeg Pharma
“Once again, we’re pleased to see that leveraging CytoReason’s computational disease models to extract insights from Poolbeg’s unique human challenge data can optimise the target discovery process. More importantly, these impressive results would not be possible without the commitment, transparency, and reciprocity of both teams.”
David Harel
CEO of CytoReason
Neel S. Madhukar, PhD
CEO of OneThree Biotech
“We are very pleased to be working with Poolbeg and to have the opportunity to deploy the ATLANTIS platform to complete the first ever AI-driven analysis of RSV disease progression data. I am delighted that Poolbeg’s unique dataset combined with OneThree’s externally validated platform have now delivered new actionable insights surrounding disease biology and drug discovery that can bring much needed treatment options for both the young and the elderly; the most vulnerable to RSV infection.”